Scarica l'app Stockscreener
20.96
3.51%
0.71
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ADPT Giù?
Forum
Previsione
Precedente Chiudi:
$20.25
Aprire:
$20.075
Volume 24 ore:
6.47M
Relative Volume:
2.68
Capitalizzazione di mercato:
$3.35B
Reddito:
$295.41M
Utile/perdita netta:
$-49.64M
Rapporto P/E:
-64.02
EPS:
-0.3274
Flusso di cassa netto:
$-29.54M
1 W Prestazione:
+19.57%
1M Prestazione:
+48.34%
6M Prestazione:
+25.51%
1 anno Prestazione:
+72.37%
Intervallo 1D:
$19.96
$21.00
Intervallo di 1 settimana:
$17.13
$21.00
Portata 52W:
$9.9551
$21.00
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Nome
Adaptive Biotechnologies Corp
Settore
Industria
Telefono
206-659-0067
Indirizzo
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs TMO, DHR, IDXX, A, NTRA
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
20.96 | 3.35B | 295.41M | -49.64M | -29.54M | -0.3274 |
TMO
Thermo Fisher Scientific Inc
|
513.03 | 190.65B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.19 | 138.86B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
551.50 | 43.50B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.01 | 38.41B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.91 | 37.51B | 2.50B | -226.32M | 71.51M | -1.6412 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Iniziato | Guggenheim | Buy |
| 2025-06-18 | Iniziato | Craig Hallum | Buy |
| 2025-03-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-12-21 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Underperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2022-02-16 | Reiterato | BTIG Research | Buy |
| 2022-02-16 | Reiterato | BofA Securities | Buy |
| 2022-02-16 | Reiterato | Goldman | Neutral |
| 2022-02-16 | Reiterato | JP Morgan | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-03-03 | Downgrade | Goldman | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Iniziato | Goldman | Buy |
| 2019-07-23 | Iniziato | BTIG Research | Buy |
| 2019-07-22 | Iniziato | BofA/Merrill | Buy |
| 2019-07-22 | Iniziato | Cowen | Outperform |
| 2019-07-22 | Iniziato | Goldman | Neutral |
| 2019-07-22 | Iniziato | Guggenheim | Buy |
| 2019-07-22 | Iniziato | William Blair | Outperform |
Mostra tutto
Adaptive Biotechnologies Corp Borsa (ADPT) Ultime notizie
Adaptive Biotechnologies Corp. Actuals & Estimates (TRADEGATE:1HM) - TradingView
BTIG Maintains a Buy Rating on Adaptive Biotechnologies (ADPT) - Insider Monkey
Adaptive Biotechnologies Corp. Actuals & Estimates (NASDAQ:ADPT) - TradingView
1HM Forecast — Price Target — Prediction for 2027 - TradingView
Adaptive Biotechnologies stock hits 52-week high at 20.82 USD By Investing.com - Investing.com Australia
Form 144 ADAPTIVE BIOTECHNOLOGIES CORPORATION For: 26 June By Investing.com - Investing.com Australia
[144] Adaptive Biotechnologies Corp SEC Filing - Stock Titan
Adaptive Biotechnologies stock hits 52-week high at 20.82 USD - Investing.com
Adaptive Biotechnologies Corp. Actuals & Estimates (FWB:1HM) - TradingView
Adaptive Biotechnologies CorpIssues $345 Million In 0% Convertible Senior Notes Due 2031SEC Filing - TradingView
Form 8K Adaptive Biotechnologies Corp For: 22 June By Investing.com - Investing.com South Africa
Adaptive Biotechnologies Prices $345 Million 0% Convertible Notes Due 2031, Adds Capped Call - TradingView
Adaptive Biotechnologies (Nasdaq: ADPT) sells $345M 0% notes and repays OrbiMed deal - Stock Titan
Adaptive Biotechnologies Corp (ADPT) Institutional Confidence - TradingKey
Insider Sell: Harlan Robins Sells 106,160 Shares of Adaptive Bio - GuruFocus
Adaptive Biotechnologies Corp (ADPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Adaptive Biotechnologies Corp (ADPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Adaptive Biotechnologies Corp (ADPT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Adaptive Biotechnologies CSO Harlan Robins sells $1.8m in stock - Investing.com UK
Adaptive Biotechnologies Corp (ADPT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Adaptive Biotechnologies Corp (ADPT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Adaptive Biotechnologies CSO Harlan Robins sells $1.8m in stock By Investing.com - Investing.com India
Adaptive Biotechnologies (ADPT) CSO sells 106K shares under 10b5-1 plan - Stock Titan
ADPT Reiterated by BTIG -- Price Target Maintained at $22 - GuruFocus
Adaptive Biotechnologies Business Separation May Unlock Greater Value - Benzinga
BTIG reiterates Adeptus Biotechnologies stock rating on business split By Investing.com - Investing.com South Africa
Analysts Are Bullish on Top Healthcare Stocks: Pasithea Therapeutics Corp (KTTA), Adaptive Biotechnologies (ADPT) - The Globe and Mail
Adaptive Biotechnologies Corp (ADPT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Adaptive Biotechnologies Corp (ADPT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering - The Manila Times
Adaptive Biotechnologies Announces Pricing of $300 Million Convertible Senior Notes Offering to Enhance Financial Flexibility - Quiver Quantitative
Adaptive Biotechnologies raises $300M zero-interest debt, buys back stock - Stock Titan
Seattle biotech looks to raise up to $288 million amid plans to spin out immune medicine business - The Business Journals
Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses - Benzinga
Stock Market Today: S&P 500, Nasdaq Futures Fall, Dow Gains Amid US-Iran Deal— SpaceX, Dave And Buster's, Western Digital In Focus (UPDATED) - Benzinga
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering - The Manila Times
Adaptive Biotechnologies chief commercial officer sells $95,000 in shares - Investing.com UK
Adaptive Biotechnologies stock falls on convertible debt plan - Investing.com
Adaptive Biotechnologies chief commercial officer sells $95,000 in shares By Investing.com - Investing.com Nigeria
Executive at Adaptive Biotechnologies (ADPT) sells 5,000 shares under 10b5-1 plan - Stock Titan
Adaptive Biotechnologies plans $250M convertible notes offering By Investing.com - Investing.com Australia
Adaptive Biotechnologies plans to separate MRD, Immune Medicine units - Investing.com
Adaptive Biotechnologies plans $250M convertible notes offering - Investing.com
Adaptive Biotechnologies stock falls on convertible debt plan By Investing.com - Investing.com India
Adaptive Biotechnologies proposes $250M convertible notes, plans MRD/Immune Medicine separation - TradingView
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses - The Manila Times
Adaptive Biotechnologies (NASDAQ: ADPT) to sell $250M converts and explore MRD–Immune Medicine split - Stock Titan
Adaptive Biotechnologies plans split: MRD tests vs AI immune unit - Stock Titan
Adaptive Biotechnologies lines up $250M note deal to repay debt, buy back shares - Stock Titan
Kennedy Capital Management LLC Trims Holdings in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Bio’s $250M Gambit: A Strategic Split Beyond the Balance Sheet - BriefGlance
Adaptive Biotechnologies Corp Azioni (ADPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.76%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):